Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) EPS (Weighted Average and Diluted) (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$32.43 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 49.04% to -$32.43 in Q4 2025 year-over-year; TTM through Dec 2025 was -$50.83, a 47.27% increase, with the full-year FY2025 number at -$50.83, up 47.27% from a year prior.
  • EPS (Weighted Average and Diluted) was -$32.43 for Q4 2025 at Spruce Biosciences, down from -$14.58 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.23 in Q4 2023 to a low of -$63.64 in Q4 2024.
  • A 4-year average of -$9.4 and a median of -$0.49 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 27569.57% in 2024, then soared 79.08% in 2025.
  • Spruce Biosciences' EPS (Weighted Average and Diluted) stood at -$0.47 in 2022, then soared by 51.06% to -$0.23 in 2023, then crashed by 27569.57% to -$63.64 in 2024, then skyrocketed by 49.04% to -$32.43 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's EPS (Weighted Average and Diluted) are -$32.43 (Q4 2025), -$14.58 (Q3 2025), and -$3.5 (Q2 2025).